Large-scale plasma-metabolome analysis identifies potential biomarkers of psoriasis and its clinical subtypes

• DOI: 10.1016/j.jdermsci.2021.03.006
• Publication Date: 2021-03-27T04:04:09Z
• Authors: Toshihiro Kishikawa; Noriko Arase; Shigeyoshi Tsuji; Yuichi Maeda; Takuro Nii; Jun Hirata; Ken Suzuki; Kenichi Yamamoto; Tatsuo Masuda; Kotaro Ogawa; Shiro Ohshima; Hidenori Inohara; Atsushi Kumanogoh; Manabu Fujimoto; Yukinori Okada
• Keywords: Metabolome

Psoriasis is an immune-mediated skin disease for which the crosstalk between genetic and environmental factors responsible. To date, no definitive diagnostic criteria psoriasis yet, specific biomarkers are required.We performed metabolome analysis to identify metabolite of its subtypes such as psoriatic arthritis (PsA) cutaneous (PsC).We constructed metabolomics profiling 130 plasma samples (42 PsA patients, 50 PsC 38 healthy controls) using a nontargeted approach.Psoriasis-control association tests showed that one (ethanolamine phosphate) was significantly increased in than controls, whereas three metabolites decreased (false discovery rate [FDR] < 0.05; XA0019, nicotinic acid, 20α-hydroxyprogesterone). In test PsC, tyramine mucic acid (FDR 0.05). Molecular pathway PsA-PsC identified enrichment vitamin digestion absorption (P = 1.3 × 10-4). Correlation network analyses elucidated subnetwork centered on aspartate among psoriasis-associated metabolites; meanwhile, major with differences primarily formed from saturated fatty acids.Our large-scale highlights novel characteristics could be used potential clinical subtypes. These findings contribute our understanding pathophysiology.